Literature DB >> 10029367

Functional digestive disorders (FDD) in the year 2000--economic impact.

S Fullerton1.   

Abstract

OBJECTIVE: The objective of this study is to quantify the future worldwide economic impact of functional gastrointestinal disease and to describe international differences that might exist between major industrialized countries.
DESIGN: This study employs an econometric projection using data from the only known survey of national economic impact of functional gastrointestinal disease. Economic costs from this survey are combined with country specific population estimates, health care spending characteristics, and growth rates to estimate economic impact for major industrial countries.
RESULTS: The estimated economic impact of functional gastrointestinal disease for eight major industrial countries is over 41 billion U.S. dollars annually. This estimate includes both direct and indirect costs of disease.
CONCLUSION: The economic impact of functional gastrointestinal disease is large. Economic estimates are useful in policy decision making regarding the allocation of health care resources.

Entities:  

Mesh:

Year:  1998        PMID: 10029367     DOI: 10.1080/11024159850191463

Source DB:  PubMed          Journal:  Eur J Surg Suppl        ISSN: 1102-416X


  11 in total

Review 1.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

Review 2.  Irritable bowel syndrome.

Authors:  S M Turner; J E Stewart; J J Alexopulos; J S Hill
Journal:  Curr Rev Pain       Date:  2000

3.  A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome.

Authors:  A Robinson; V Lee; A Kennedy; L Middleton; A Rogers; D G Thompson; D Reeves
Journal:  Gut       Date:  2005-08-12       Impact factor: 23.059

Review 4.  Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures.

Authors:  M Camilleri; D E Williams
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

Review 5.  Costs of irritable bowel syndrome in the UK and US.

Authors:  Stefanie Maxion-Bergemann; Frank Thielecke; Florian Abel; Rito Bergemann
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 6.  New technologies to investigate the brain-gut axis.

Authors:  Abhishek Sharma; Dina Lelic; Christina Brock; Peter Paine; Qasim Aziz
Journal:  World J Gastroenterol       Date:  2009-01-14       Impact factor: 5.742

7.  Affective reactivity to daily stressors and long-term risk of reporting a chronic physical health condition.

Authors:  Jennifer R Piazza; Susan T Charles; Martin J Sliwinski; Jacqueline Mogle; David M Almeida
Journal:  Ann Behav Med       Date:  2013-02

Review 8.  Irritable Bowel Syndrome: Peripheral Mechanisms and Therapeutic Implications.

Authors:  Iulia-Maria Crişan; Dan Lucian Dumitraşcu
Journal:  Clujul Med       Date:  2014-05-30

9.  Estimating the burden of irritable bowel syndrome: analysis of a nationwide korean database.

Authors:  Hye-Kyung Jung; Youn Hee Kim; Joo Yeon Park; Bo Hyoung Jang; Sun-Young Park; Mi-Hee Nam; Myung-Gyu Choi
Journal:  J Neurogastroenterol Motil       Date:  2014-04-30       Impact factor: 4.924

10.  Pimpinella anisum in modifying the quality of life in patients with functional dyspepsia: A double-blind randomized clinical trial.

Authors:  S Ashraffodin Ghoshegir; Mohammad Mazaheri; Alireza Ghannadi; Awat Feizi; Mahmoud Babaeian; Maryam Tanhaee; Mehrdad Karimi; Peyman Adibi
Journal:  J Res Med Sci       Date:  2014-12       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.